Working in the Computational Arrhythmia Lab, I am interested in using machine-learning-based analytical approaches to gain novel, interpretable insights into the pathophysiological mechanisms of arrhythmias and translate that into clinical practice. In my leisure, I like writing and reading poems, listening and (trying to) sing Indian classical music, apart from being an avid runner.
Honors & Awards
Stanford School of Medicine Dean's Fellowship, Stanford University
Best student in MS1 and MS2 years, and best all-rounder of the graduating batch, JIPMER (2014-2019)
Gold medals: Anatomy, Biochemistry, Pathology, Psychiatry, Orthopedics, Cardiology, Anesthesiology, JIPMER (2014-2019)
MBBS, JIPMER, Medical school (2019)
TARGETING SYNCHRONIZED ELECTROGRAM ISLANDS WITHIN ATRIAL FIBRILLATION FOR ABLATION
ELSEVIER SCIENCE INC. 2022: 3
View details for Web of Science ID 000781026600004
A MORPHOLOGICAL OPERATION-BASED APPROACH TO AUTOMATICALLY SEPARATE AND LABEL LEFT ATRIUM BODY AND PULMONARY VEINS
ELSEVIER SCIENCE INC. 2022: 1244
View details for Web of Science ID 000781026601343
UNSUPERVISED MACHINE LEARNING IDENTIFIES PHENOTYPES FOR ATRIAL FIBRILLATION THAT PREDICT ACUTE ABLATION SUCCESS
ELSEVIER SCIENCE INC. 2022: 51
View details for Web of Science ID 000781026600052
Identifying Atrial Fibrillation Mechanisms for Personalized Medicine.
Journal of clinical medicine
2021; 10 (23)
Atrial fibrillation (AF) is a major cause of heart failure and stroke. The early maintenance of sinus rhythm has been shown to reduce major cardiovascular endpoints, yet is difficult to achieve. For instance, it is unclear how discoveries at the genetic and cellular level can be used to tailor pharmacotherapy. For non-pharmacologic therapy, pulmonary vein isolation (PVI) remains the cornerstone of rhythm control, yet has suboptimal success. Improving these therapies will likely require a multifaceted approach that personalizes therapy based on mechanisms measured in individuals across biological scales. We review AF mechanisms from cell-to-organ-to-patient from this perspective of personalized medicine, linking them to potential clinical indices and biomarkers, and discuss how these data could influence therapy. We conclude by describing approaches to improve ablation, including the emergence of several mapping systems that are in use today.
View details for DOI 10.3390/jcm10235679
View details for PubMedID 34884381
Sa406 PREDICTING POST-PRANDIAL GLYCEMIA FROM GASTRIC EMPTYING IN TYPE 1 DM PATIENTS
2021; 160 (6)
View details for DOI 10.1016/S0016-5085(21)01888-6
Phenotypic Characterization Of Functional Defecatory Disorders Using Simultaneous MR Defecography And Manometry
2021; 160 (6): S101-102
View details for DOI 10.1016/S0016-5085(21)00988-4
Refining The Measurements Of Anal Rest And Squeeze Pressures During High Resolution Anorectal Manometry
2021; 160 (6)
View details for DOI 10.1016/S0016-5085(21)00800-3
Constipation and Fecal Incontinence in the Elderly.
Current gastroenterology reports
2020; 22 (11): 54
To review the epidemiology, pathogenesis, clinical features, and management of primary constipation and fecal incontinence in the elderly.Among elderly people, 6.5%, 1.7%, and 1.1% have functional constipation, constipation-predominant IBS, and opioid-induced constipation. In elderly people, the number of colonic enteric neurons and smooth muscle functions is preserved; decreased cholinergic function with unopposed nitrergic relaxation may explain colonic motor dysfunction. Less physical activity or dietary fiber intake and postmenopausal hormonal therapy are risk factors for fecal incontinence in elderly people. Two thirds of patients with fecal incontinence respond to biofeedback therapy. Used in combination, loperamide and biofeedback therapy are more effective than placebo, education, and biofeedback therapy. Vaginal or anal insert devices are another option. In the elderly, constipation and fecal incontinence are common and often distressing symptoms that can often be managed by addressing bowel disturbances. Selected diagnostic tests, prescription medications, and, infrequently, surgical options should be considered when necessary.
View details for DOI 10.1007/s11894-020-00791-1
View details for PubMedID 32839874
Diffuse large B-Cell lymphoma associated with paraneoplastic Guillain-Barré syndrome: A diagnostic and therapeutic challenge.
Hematology/oncology and stem cell therapy
Paraneoplastic neurological syndromes are a rare manifestation of non-Hodgkin lymphoma and can make treatment of these patients more challenging. We report the case of a 67-year-old man with high grade diffuse large B-cell lymphoma who presented with severe paraneoplastic Guillain-Barré syndrome. He was treated with intravenous immunoglobulin therapy and definitive chemoimmunotherapy, and achieved a full neurological recovery. In this report, we discuss various mechanisms of neurological dysfunction seen in lymphomas. Prompt oncologic treatment and immunotherapy for Guillain-Barré syndrome if instituted concurrently and early in the course of the disease can be associated with the best outcomes.
View details for DOI 10.1016/j.hemonc.2020.05.008
View details for PubMedID 32470333